CRISPR-Cas systems, derived from prokaryotic adaptive immunity, have revolutionized genetic engineering.  This technology utilizes a guide RNA (gRNA) molecule to direct the Cas nuclease, most commonly Cas9, to a specific genomic locus.  Cas9 then generates a double-strand break, stimulating endogenous DNA repair pathways â€“ non-homologous end joining (NHEJ) leading to insertions or deletions (indels), or homology-directed repair (HDR) enabling precise gene editing via donor DNA templates.  While highly efficient, CRISPR-Cas9 exhibits off-target effects due to gRNA mismatches, necessitating rigorous validation.  Advancements include the development of higher-fidelity Cas variants and base editors, which modify single nucleotides without causing double-strand breaks, mitigating off-target risks.  Furthermore, CRISPR systems are expanding beyond gene editing, encompassing gene regulation via deactivated Cas nucleases (dCas9) fused to transcriptional activators or repressors, and enabling multiplex gene editing for complex trait manipulation.  Despite ethical considerations and ongoing refinement, CRISPR technology promises transformative applications in diverse fields, including disease treatment, agriculture, and synthetic biology.